Pipeline of Angina Market (Angina Pectoris) Reviewed for H2 2015

Mar 17, 2016, 02:00 ET from RnR Market Research

PUNE, India, March 17, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Angina (Angina Pectoris) - Pipeline Review, H2 2015" to its store. The report provides an overview of the Angina (Angina Pectoris)'s therapeutic pipeline with comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects.

Complete report on H2 2015 pipeline review of Angina (Angina Pectoris) with 68 market data tables and 17 figures, spread across 83 pages is available at http://www.rnrmarketresearch.com/angina-angina-pectoris-pipeline-review-h2-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Angina (Angina Pectoris) Pipeline Review, H2 2015 report include Baxalta Incorporated, Bayer AG, Cardiolynx AG, Gilead Sciences, Inc., Juventas Therapeutics, Inc., Kuhnil Pharmaceutical Co., Ltd., Lacer, S.A., Lee's Pharmaceutical Holdings Limited, LegoChem Biosciences, Inc, Milestone Pharmaceuticals, Inc., Taxus Cardium Pharmaceuticals Group Inc. and ViroMed Co., Ltd. Drug profiles discussed in this research report includes aladorian sodium, alferminogene tadenovec, BAY-606583, CLC-1201, CLC-1280, eleclazine, JVS-100, KI-1007, LA-419, LA-8045, MSP-2017, Small Molecule to Activate Soluble uanylate Cyclase for Angina Pectoris, Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke, Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia, Stem Cell Therapy for Cardiovascular Diseases, VM-202 and ZK-001.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=449117 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Angina (Angina Pectoris) and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Angina (Angina Pectoris) pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research report titled on Rheumatoid Arthritis - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Rheumatoid Arthritis Pipeline market research report of 1175 pages is available at http://www.rnrmarketresearch.com/rheumatoid-arthritis-pipeline-review-h2-2015-market-report.html .

Explore more reports on Neurology therapeutics

About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345


SOURCE RnR Market Research